🇺🇸 Mesenchymal Stem Cells in United States

10 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 23 April 2025 – 23 April 2026
• Total reports: 10

Most-reported reactions

1. Bronchitis — 1 report (10%)
2. Drug Ineffective For Unapproved Indication — 1 report (10%)
3. Gait Disturbance — 1 report (10%)
4. Illness — 1 report (10%)
5. Joint Swelling — 1 report (10%)
6. Pain In Extremity — 1 report (10%)
7. Peripheral Swelling — 1 report (10%)
8. Respiratory Failure — 1 report (10%)
9. Squamous Cell Carcinoma — 1 report (10%)
10. Wrong Technique In Product Usage Process — 1 report (10%)

Source database →

Frequently asked questions

Is Mesenchymal Stem Cells approved in United States?

Mesenchymal Stem Cells does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Mesenchymal Stem Cells in United States?

Ottawa Hospital Research Institute is the originator. The local marketing authorisation holder may differ — check the official source linked above.